Skip to main content
Delfa

← All assets

Idalopirdine

7 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

7

Ongoing

0

Recruiting

0

Completed

6

Sites

472

Countries

35

Endpoints

88

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 88 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
2
Phase 2
1
Phase 3
4

Trials by status

Completed
6
Terminated
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Behavior / neuropsychiatric
40
Global cognition
30
Function / daily living
9
Safety / tolerability / PK
7
Other (unclassified)
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 58 of 88 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

20

Neuropsychiatric Inventory (NPI)Behavior

20

Mini-Mental State Examination (MMSE)Cognition

10

ADCS-Activities of Daily Living (ADCS-ADL)Function

8

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

7 of 7

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
STAR ExtensionLong-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

Idalopirdine

Alzheimer’s disease

Age ≥50Ph 3Completed258Jul 2017-results
STARBEAMIdalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

Idalopirdine

Alzheimer’s disease

mild-to-moderate ADPh 3Completed162Dec 20163results
STARSHINEStudy of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

Idalopirdine

Alzheimer’s disease

mild-to-moderate ADPh 3Completed137Jul 20163results
STARBRIGHTStudy of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor

Idalopirdine

Alzheimer’s disease

mild-to-moderate ADPh 3Completed107Jan 20173results
NCT01019421Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease

Idalopirdine

Alzheimer’s disease

Alzheimer's diseasePh 2Completed51Dec 20111
NCT02340195Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function

Idalopirdine

Alzheimer’s disease

Healthy volunteersPh 1Completed1Sep 2015-
NCT03307993Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease

Idalopirdine

Alzheimer’s disease

Alzheimer's diseasePh 1Terminated1Feb 2018-

Showing 1-7 of 7 trials